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Background: Noninvasive positive pressure ventilation
(NPPV) with a facemask (FM) is effective in patients with acute
exacerbation of their chronic obstructive pulmonary disease.
Whether it is feasible to treat these patients with NPPV delivered
by a helmet is not known.
Methods: Over a 4-month period, the authors studied 33
chronic obstructive pulmonary disease patients with acute ex-
acerbation who were admitted to four intensive care units and
treated with helmet NPPV. The patients were compared with 33
historical controls treated with FM NPPV, matched for simpli-
fied acute physiologic score (SAPS II), age, PaCO2, pH, and PaO2:
fractional inspired oxygen tension. The primary endpoints
were the feasibility of the technique, improvement of gas ex-
change, and need for intubation.
Results: The baseline characteristics of the two groups were
similar. Ten patients in the helmet group and 14 in the FM
group (P  0.22) were intubated. In the helmet group, no
patients were unable to tolerate NPPV, whereas five patients
required intubation in the FM group (P  0.047). After 1 h of
treatment, both groups had a significant reduction of PaCO2
with improvement of pH; PaCO2 decreased less in the helmet
group (P  0.01). On discontinuing support, PaCO2 was higher
(P  0.002) and pH lower (P  0.02) in the helmet group than
in the control group. One patient in the helmet group, and 12 in
the FM group, developed complications related to NPPV (P <
0.001). Length of intensive care unit stay, intensive care unit,
and hospital mortality were similar in both groups.
Conclusions: Helmet NPPV is feasible and can be used to treat
chronic obstructive pulmonary disease patients with acute ex-
acerbation, but it does not improve carbon dioxide elimination
as efficiently as does FM NPPV.
SEVERAL randomized studies have found that in patients
with acute exacerbation of chronic obstructive pulmo-
nary disease (COPD), noninvasive positive pressure ven-
tilation (NPPV) added to standard therapy reduces the
need for tracheal intubation, rate of complications, in-
tensive care unit (ICU) length of stay,1–3 and mortality.2
Two recent meta-analyses4,5 concluded that NPPV
should be considered a first-line intervention in patients
with acute exacerbation of COPD. A recent American-
European Consensus Conference recommended that in
patients hospitalized for exacerbation of COPD with
rapid clinical deterioration, NPPV should be considered
to prevent further impairment in gas exchange, respira-
tory workload, and need for tracheal intubation.6
Noninvasive ventilation is usually delivered through a
nasal mask or facemask (FM). The nasal mask is better
tolerated, but the FM seems more appropriate in patients
with severe decompensation, who are often mouth
breathers and cooperate poorly with treatment.2,6–8 In
some patients, pain, discomfort, or claustrophobia may
result in intolerance of the mask and require discontin-
uation of noninvasive ventilation and intubation. Despite
continuous improvements in mask design and materials,
skin necrosis is frequent in patients receiving NPPV for
long periods.6,7
In an attempt to improve tolerance, we recently devel-
oped a transparent helmet that allows patients to see,
read, and speak during NPPV.9 In that study, we showed
the efficacy of NPPV delivered by the helmet in critically
ill patients without COPD but with acute hypoxemic
respiratory failure.
The helmet has important advantages: (1) It is well
tolerated and allows a satisfactory environmental inter-
action for patients. (2) Its fixation system should mini-
mize the risk of cutaneous lesions. (3) Unlike the FM, it
can be applied to any patient regardless of differences in
facial contour.9
The helmet was initially proposed to deliver continu-
ous positive airway pressure as an out-of-hospital treat-
ment for patients with pulmonary edema. To our knowl-
edge, the helmet with positive pressure ventilation has
never been used to treat ICU patients with acute exac-
erbation of COPD.
The aim of this case-control study was to investigate
the feasibility and efficacy of NPPV delivered by the
helmet in adults with acute exacerbation of COPD, in
comparison to NPPV delivered by a standard FM.
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Methods
Equipment
The helmet (CaStar; Starmed, Mirandola, Italy) (fig. 1)
is made of transparent latex-free polyvinyl chloride and
is secured by two armpit braces to a pair of hooks on the
plastic ring that joins the helmet to a soft collar. The
collar adheres to the neck and allows a sealed connec-
tion; the pressure increase during ventilation increases
adherence of the collar to the neck and shoulders while
avoiding air leakage.9 The whole apparatus is connected
to an ICU ventilator by a standard respiratory circuit. The
two ports of the helmet act as inlet and outlet for in-
spiratory and expiratory gas flows. The inspiratory and
expiratory valves are those of the mechanical ventilator.
A specific connector placed in the plastic ring can be
used to allow the passage of a nasogastric tube while
avoiding air leak. This connection also permits patients
to drink through a straw or to be fed a liquid diet.
In contrast to FM NPPV, with helmet-delivered NPPV
patients receive only part of the large volumes delivered
by the ventilator after inspiratory trigger activation; the
rest of the volume is compressed around the head, pres-
surizing the helmet. It is therefore impossible to measure
patient tidal volumes and flows with conventional bed-
side monitoring. Occasionally, patient–machine dyssyn-
chrony may occur during helmet NPPV, in which case
the patient can breathe unassisted into the pressurized
helmet, as with free-flow continuous positive airway
pressure.
The internal volume surrounding the head varies be-
tween 6 and 8 l, but this usually does not represent a
problem for rebreathing, provided that sufficient levels
of pressure support are delivered.9 When measuring
partial pressure of inspired carbon dioxide and end-tidal
carbon dioxide in healthy volunteers at 10 cmH2O pres-
sure support (Appendix), we showed that carbon diox-
ide rebreathing with the helmet is always less than 1.5%
and is similar to that detected with the FM. A new
version of this helmet, recently developed, has antias-
phyxia mechanisms and two inner inflatable cushions to
increase comfort and reduce the internal volume.
Study Design and Patient Selection
We conducted a case control study involving all con-
secutive adult patients with acute decompensation of
COPD, eligible for treatment with NPPV between No-
vember 2000 and February 2001, who were admitted to
four ICUs in Italy (Università Cattolica del Sacro Cuore;
Servizio di Anestesia CTO; Università dell’Insubria; and
Unità di Terapia Intensiva Respiratoria, Ospedale
Forlanini).
On the basis of clinical history, physical examination,
and chest radiograph, the patients were determined to
have COPD with respiratory acidosis and an elevated
bicarbonate level. Additional criteria for enrollment
were similar to those proposed by Brochard et al.2 and
included an exacerbation of dyspnea lasting less than 2
weeks and at least two of the following: respiratory rate
above 30 breaths per minute, PaO2 below 45 mmHg, and
arterial pH below 7.35 after breathing at fractional in-
spired oxygen tension (FIO2) below 0.35 for at least
10 min.
Patients with any of the following were excluded:
requirement for emergency intubation or cardiopulmo-
nary resuscitation, respiratory arrest, severe hemody-
namic instability, encephalopathy; respiratory failure
caused by neurologic disease or status asthmaticus; more
than two new organ failures10 (e.g., simultaneous pres-
ence of renal and cardiovascular failures), tracheostomy,
or facial deformities. No patients received active
humidification.
An ad hoc ethics committee approved the protocol,
and all patients gave informed consent. For each patient
treated with helmet NPPV, one matched historical con-
trol was selected according to predetermined criteria.
The patients and controls all received similar medical
treatment as clinically appropriate, including inhaled -2
agonists, steroids, and antibiotics. The SAPS II was cal-
culated 24 h after admission to the ICU.11 Each team that
enrolled patients had ample experience with noninva-
sive ventilation.
Helmet Positive Pressure Ventilation
During NPPV, the ventilator was connected to the
helmet with conventional tubing. The head of the bed
was kept at a 45-degree angle. Once the helmet was
positioned, a baseline pressure support level was set at
10 cmH2O and was raised in increments of 2–3 cmH2O
to obtain patient comfort, respiratory rate lower than
25 breaths/min, and disappearance of accessory muscle
activity, evaluated by palpating the sternocleidomastoid
muscle.12 Positive end expiratory pressure (PEEP) was
set at 5–7 cmH2O to counterbalance the possible pres-
Fig. 1. A patient with the helmet connected to the ventilator. AB
 armpit braces; EV expiratory valve; IV  inspiratory valve;
P  port of the helmet connected to the conventional respira-
tory circuit; SC  seal connection, which allows the passage of
a nasogastric tube or permits the patient to drink through a
straw or to be fed a liquid diet. Photograph printed with the
permission of the patient.
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ence of PEEPi. We used both flow and pressure triggers;
the pressure trigger was set at 1 cmH2O and the flow
trigger at 5 l/s. If tracheal intubation was required, the
helmet was easily removed and the patient intubated
within few seconds.
FM Group
The control patients were selected from a group of
198 patients admitted to the ICU in the 12 months
preceding the study with a diagnosis of respiratory fail-
ure due to acute exacerbation of COPD and treated with
FM NPPV. The control group had the same enrollment
criteria as the helmet group. The physician who selected
the controls did not know the results of the study and
was not informed about the course of treatment.
For each patient treated with helmet NPPV, one
matching control was selected according to the follow-
ing criteria: severity of illness on admission within four
points as assessed by SAPS II11 and age within 10 yr of
the treated patients; PaCO2 within 8 mmHg of the values
of the treated patients; arterial pH on admission within
0.04 points of the treated patients; and PaO2:FIO2 ratio
(while receiving FIO2 below 0.35 by a Venturi mask
(Deaflux Line; DEAS, Castelbolognese, RA, Italy) within
10 points of the treated patients. When matching each
patient we gave priority to PaCO2, pH, age, and SAPS II
score.
FM Positive Pressure Ventilation
During NPPV, the ventilator was connected with con-
ventional tubing to a clear FM with an inflatable soft
cushion seal (Gibeck, Upplands, Sweden, or Vitalsigns
Inc, Towota, NJ and Benefit, Puritan Bennett Co., Over-
land Park, KS). The mask was secured by head straps
while avoiding a tight fit, and the head of the bed was
kept elevated at 45-degree angle. In most patients, a
protective hydrocolloid sheet was applied over the nasal
bridge. For patients with a nasogastric tube, a seal con-
nector in the dome of the mask was used to minimize air
leakage. After the mask was secured, the initial level of
10 cmH2O pressure support was gradually increased in
increments of 2–3 cmH2O to obtain a respiratory rate of
less than 25 breaths/min, disappearance of accessory
muscle activity (evaluated by palpating the sternocleido-
mastoid muscle),12 and patient comfort. PEEP was set at
5–7 cmH2O to counterbalance the intrinsic PEEP level.
The pressure trigger was set at 1 cmH2O or the flow
trigger at 5 l/s.
Monitoring and Weaning
All patients had continuous electrocardiography and
arterial oxygen saturation monitoring. We used two
types of mechanical ventilators: the Servo 300 Siemens
(Siemens Elema, Uppsala, Sweden) or the Evita 4 (Dräger
Medical AG, Lübeck, Germany). In both groups, ventila-
tor settings were adjusted on the basis of continuous
pulse-oxymetry and repeated measurements of arterial
blood gases. No patient received sedatives.
Duration of NPPV was standardized in both groups
according to a standard protocol13: NPPV was delivered
almost continuously in the first 24 h, with short intervals
of spontaneous breathing with oxygen supplementation;
in the subsequent days the length of NPPV was gradually
decreased, according to the clinical response (but never
 6 h/day). NPPV was discontinued if the patient had a
normal mental status; was hemodynamically stable;
maintained a respiratory rate lower than 30 breaths/min;
had an arterial pH 7.35 or greater; and had a PaO2 greater
than 55 mmHg, with FIO2 0.35 or peripheral oxygen
saturation 90% or higher, without ventilatory support
and in the absence of dyspnea, activation of accessory
muscles of respiration, and paradoxical abdominal
motion.
Criteria for Endotracheal Intubation
Patients who were not treated successfully with NPPV
were intubated with cuffed endotracheal tubes (ID, 7.5–
8.5 mm) and mechanically ventilated. The predeter-
mined major criteria for tracheal intubation were similar
to those used by Brochard et al.2 and included respira-
tory arrest, respiratory pauses with loss of conscious-
ness, psychomotor agitation making nursing care impos-
sible and requiring sedation, heart rate below 50 beats
per minute with loss of alertness, and hemodynamic
instability with systolic arterial blood pressure below
70 mmHg; development of conditions requiring intuba-
tion either to protect the airways (coma or seizure dis-
orders) or to manage copious tracheal secretions; and
inability of the patient to tolerate the FM or helmet,
including discomfort, claustrophobia, or pain.2 Patients
with unsuccessful treatment because of intolerance of
noninvasive ventilation included those who refused to
continue noninvasive ventilation despite improved gas
exchanges, no difficulty managing their secretions, im-
provement of dyspnea, and disappearance of accessory
muscle activity. Minor criteria were respiratory rate
above 35 breaths/min and above the value on admission;
arterial pH below 7.30 and below the value on admis-
sion; and PaO2 below 45 mmHg despite NPPV. The
presence of two minor criteria after the first hour of
NPPV was considered an indication for intubation. Major
and minor criteria were identical for both groups.
Endpoints and Definitions
The primary endpoints were the need for tracheal
intubation and the improvement of gas exchanges at any
time during the study and the incidence of complica-
tions related to NPPV (facial skin necrosis, gastric disten-
sion, and intolerance). Secondary endpoints included
complications not present on admission (such as venti-
lator-associated pneumonia or extrapulmonary sepsis),
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duration of ventilatory assistance, length of hospital stay,
and ICU mortality.
Arterial blood gas levels were determined at baseline,
while breathing through a Venturi mask with FIO2 below
0.35, at 1 h during NPPV, when clinically needed, and at
discontinuation of support that corresponded to (1) the
moment of tracheal intubation for those not successfully
treated with NPPV, or (2) definitive weaning from non-
invasive ventilation for those successfully treated. Im-
provement in gas exchange was defined as an increase in
pH over 7.34 and decreases in PaCO2 to at least 10 points
below baseline. Improvement in gas exchange was eval-
uated within 1 h after study entry (initial improvement)
and over time (sustained improvement). Sustained im-
provement in gas exchange was defined as the ability to
maintain the improvement in gas exchanges without
intubation until NPPV was discontinued.
Sepsis, severe sepsis, and septic shock were defined
according to consensus guidelines.14 Patients who devel-
oped clinical manifestations of pneumonia15 underwent
bronchoscopy with bronchoalveolar lavage.16 The meth-
ods and laboratory procedures followed consensus
guidelines.17 Bacterial pneumonia was diagnosed when
at least 10,000 colony-forming units of bacteria/ml were
measured in bronchoalveolar lavage fluid.17 Multiple or-
gan failure was defined according to previously de-
scribed criteria.10
Data Analysis
Results are given as mean  SD. Demographic and
physiologic characteristics of the two groups were com-
pared using the Student t test for continuous data (sep-
arate variance estimates were used when variances were
significantly different) and the Mantel-Haenszel ex-
tended chi-square test for categorical data. The Fisher
exact test (two-tailed) was used when appropriate (ex-
pected number of cases per cell  5).18 The SPSS pack-
age (SPSS Inc., Chicago, IL) was used for all analyses.
A precise calculation of sample size was not possible in
this study. Calculation of sample size was therefore
based on preexisting data to estimate the baseline rate of
the primary outcome, but no data on the intubation rate
of COPD patients with acute exacerbation treated with
the helmet were available before the present study.
Results
Characteristics of the Patients and Etiology of Acute
Respiratory Failure
From November 2000 to February 2001, 108 patients
with acute respiratory failure caused by exacerbation of
COPD were admitted to the participating ICUs. Twenty-
three patients were already tracheostomized, 15 were
treated with nasal or FM in the emergency department
or ICU, 35 were already intubated, and two refused to
participate. The other 33 met the enrollment criteria and
were treated with helmet NPPV. These patients were
compared with 33 matched controls treated with the
FM. The baseline characteristics, comorbid conditions,
and causes of acute respiratory failure of the two groups
were similar except that the heart rate was higher in the
helmet group (table 1).
Outcome Variables
After 1 h of treatment, both groups had significant
reductions of PaCO2 (12% in the helmet group; 20% in the
FM group) with an improvement of pH compared to
baseline. However, the decrease in PaCO2 was less in the
helmet group (75  15 vs. 66  15 mmHg, P  0.01)
(table 2). Moreover, at discontinuation of support, PaCO2
values for patients receiving helmet NPPV were higher
Table 1. Baseline Characteristics of the Two Groups
Helmet
(n  33)
Mask
(n  33) P
Patient characteristics
Male, No. (%) 24 (69) 25 (72) 0.50
SAPS II, m (SD) 36 (8) 36 (6) 0.99
Age (yr), m (SD) 74 (8) 73 (6) 0.64
GCS, m (SD) 14 (1) 14 (1) 0.11
FEV1, (% of predicted),
m (SD)
33 (4) 31 (4) 0.32
BMI, m (SD)* 25 (4) 27 (5) 0.10
Comorbid conditions, No. (%)
Fibrothorax 2 (6) 2 (6) 0.69
Heart ischemic disease 7 (21) 5 (15) 0.37
Hypertension 8 (24) 8 (24) 0.61
Diabetes 7 (21) 6 (18) 0.50
Solid tumors 2 (6) 2 (6) 0.69
None 7 (21) 10 (30) 0.31
Condition exacerbating COPD,
No. (%)
Community pneumonia 10 (30) 9 (27) 0.50
Extrapulmonary sepsis 6 (18) 5 (15) 0.50
Cardiac decompensation 7 (21) 4 (12) 0.25
Bronchospasm 6 (18) 9 (27) 0.28
Viral infection 4 (12) 6 (18) 0.36
Basal values
WBC count (cells  10,000),
m (SD)
11,6 (5) 10,6 (4) 0.40
PaCO2 (mmHg), m (SD) 86 (17) 82 (15) 0.22
PaO2:FIO2, m (SD) 142 (36) 155 (32) 0.14
pH, m (SD) 7.25 (0.07) 7.25 (0.04) 0.70
Respiratory rate (breaths/
min), m (SD)
37 (12) 34 (3) 0.27
Body temperature (C°), m
(SD)
37 (0.7) 37 (0.7) 0.96
Systolic blood pressure
(mmHg), m (SD)
133 (18) 141 (20) 0.11
Heart rate (bpm), m (SD) 111 (24) 100 (15) 0.03
* Body mass index (BMI) is calculated with the following formula: body weight
(kg)/height2 (m). Nine BMI values were missing (four in the helmet group and
five in the mask group).
bpm  beats per minute; COPD  chronic obstructive pulmonary disease;
FEV1  forced expiratory volume in one second; FIO2  fractional inspired
oxygen tension; GCS  Glasgow Coma Score; m  mean; PaCO2  arterial
carbon dioxide tension; PaO2  arterial oxygen tension; SAPS II  Simplified
Acute Physiologic Score II; SD standard deviation; WBC white blood cell.
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than those treated with FM NPPV (68  18 vs. 57  9
mmHg, P  0.002) and pH was significantly lower
(7.35  0.09 vs. 7.39  0.05, P  0.02) (table 2). One
patient in the helmet group who had 106 mmHg PaCO2
with pH 7.25 on admission refused to continue NPPV or
any other medical therapy after 3 h of treatment. He left
the hospital alive after 36 h.
Both groups had similar improvement of PaO2:FIO2.
Within the first hour of NPPV, 16 patients (48%) in the
helmet group and 19 (57%) in the FM group had an
improvement in gas exchange (P  0.62). PaO2:FIO2
improved over time in 20 (60%) of the 33 patients in the
helmet group and in 19 (57%) of the 33 treated with FM
(P  0.50). Respiratory rates were not different in the
two groups over time.
The levels of PEEP applied were similar in the two
groups. The levels of pressure support in the helmet
group were higher than in the FM group (P 0.001) and
without major air leaks. Duration of NPPV was similar
(P  0.25) (table 2).
Ten patients (30%) in the helmet group and 14 (42%)
in the FM group (P 0.22) were not successfully treated
with NPPV and were intubated. All of the intubations (10
patients) in the helmet group and half of those (seven
patients) in the FM group occurred during the first 24 h
of treatment. The reasons for NPPV treatment failure and
tracheal intubation of the two groups are reported in
figure 2. Six patients (18%) in the helmet group and
seven patients (21%) in the FM group failed to respond
to noninvasive ventilation within the first 12 h of treat-
ment (P  0.49). In the helmet group, no patients were
unable to tolerate NPPV, whereas 5 of the 14 FM patients
(36%) required intubation (P  0.047). Length of stay in
the ICU and mortality in the ICU and hospital were not
different between the groups.
Table 2. Outcome Variables
Helmet (n  33) Mask (n  33) P
Baseline
Level of pressure support (cmH2O), m (SD) 20 (5) 15 (7) 0.0001
PEEP (cmH2O), m (SD) 6 (2) 5 (1) 0.11
Duration of NPPV (h), m (SD) 39 (42) 30 (21) 0.25
No. of endotracheal intubations, No. (%) 10 (30) 14 (42) 0.22
Initial improvement in gas exchanges, No. (%) 16 (48) 19 (57) 0.62
Sustained improvement in gas exchanges without
intubation, No. (%)
20 (60) 19 (57) 0.50
Length of stay in ICU (days), m (SD) 15 (15) 18 (22) 0.40
ICU mortality, No. (%) 3 (9) 4 (12) 0.49
Hospital mortality, No. (%)* 7 (21) 10 (30) 0.28
After 1 h of treatment
PaCO2 (mmHg), m (SD) 75 (15) 66 (15) 0.01
PaO2:FIO2, m (SD) 193 (43) 204 (64) 0.30
pH, m (SD) 7.32 (0.07) 7.34 (0.06) 0.12
Respiratory rate (breaths/min), m (SD) 29 (6) 28 (3) 0.72
Body temperature (C°), m (SD) ND ND —
Systolic blood pressure (mmHg), m (SD) 127 (23) 131 (23) 0.26
Heart rate (bpm), m (SD) 109 (18) 91 (13) 0.001
At end of treatment†
PaCO2 (mmHg), m (SD) 68 (18) 57 (9) 0.002
PaO2:FIO2, m (SD) 211 (56) 204 (37) 0.60
pH, m (SD) 7.35 (0.09) 7.39 (0.05) 0.02
Respiratory rate (breaths/min), m (SD) 27 (9) 26 (4) 0.62
Body temperature (C°), m (SD) 36.9 (0.6) 37 (0.6) 0.90
Systolic blood pressure (mmHg), m (SD) 142 (20) 130 (21) 0.01
Heart rate (bpm), m (SD) 102 (22) 86 (11) 0.001
* Hospital deaths include the intensive care unit (ICU) deaths. † End of treatment values correspond to discontinuation of support for successful patients and to
the time of endotracheal intubation for patients not responding to noninvasive positive pressure ventilation (NPPV).
bpm  beats per minute; FIO2  fractional inspired oxygen tension; m  mean; ND  not done; PaCO2  arterial carbon dioxide tension; PaO2  arterial oxygen
tension; PEEP  positive end expiratory pressure; SD  standard deviation.
Fig. 2. Timing and reasons for tracheal intubation. No patients
failed to respond to NPPV because of helmet intolerance,
whereas 5 of the 14 patients (36%) in the FM group required
intubation (P  0.047).
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Outcome of Patients Treated Successfully and
Unsuccessfully
After stratification by treatment failure or success, the
23 successfully treated patients in the helmet group and
the 19 in the FM group had similar characteristics at
baseline, except that PaO2:FIO2 was higher in the FM
group. After 1 h of NPPV, PaCO2 decreased by 19% in the
helmet group and by 24% from baseline in the FM group
(P  0.004) (table 3). At discontinuation of support,
there was a 30% decrease of PaCO2 from baseline in both
groups and the pH was similar. In comparison to the 31%
decrease in PaCO2 in the 14 FM patients who were not
successfully treated, the 10 helmet NPPV patients who
were not successfully treated had only a 6% decrease in
PaCO2 at the time of intubation (P  0.009), their pH was
significantly lower (P  0.001), and their treatment was
deemed unsuccessful earlier (after 12 8 h of noninvasive
ventilation compared to 29  23 h, P  0.02) (table 3).
Complications and Lethal Events
The number of patients who developed complications
after the study entry was similar in each group. Five
(15%) in the helmet group and four (12%) in the FM
group developed nosocomial pneumonia after study en-
try (P  0.50) (table 4). All incidents occurred after the
failure of NPPV treatment and tracheal intubation. The
causative agents were Pseudomonas aeruginosa (three
patients), Klebsiella pneumoniae (one patient), and
Acinetobacter (one patient) in the helmet group, and P.
aeruginosa (three patients) in the FM group; in the
other patient the causal agent was not identified.
No patient developed skin necrosis, gastric distension,
conjunctivitis, or intolerance during NPPV in the helmet
group in comparison with 12 patients (36%) who did in
the FM group (P  0.001) (table 4). One patient with
severe malnutrition who was ventilated with the helmet
for 48 h developed a deep venous thrombosis of the left
Table 3. Outcome Variables in Patients Treated Successfully and Unsuccessfully
Treatment Success Treatment Failure
Helmet (n  23) Mask (n  19) P Helmet (n  10) Mask (n  14) P
Baseline
SAPS II, m (SD) 38 (8) 34 (3) 0.07 33 (8) 38 (7) 0.06
Age (y), m (SD) 76 (8) 72 (5) 0.08 70 (6) 74 (3) 0.02
GCS, m (SD) 14 (1) 14 (1) 0.47 14 (1) 13 (1) 0.47
BMI, m (SD)* 26 (3) 28 (6) 0.12 23 (4) 25 (4) 0.10
Level of pressure support (cmH2O), m (SD) 21 (5) 12 (3) 0.0001 22 (4) 11 (2) 0.001
PEEP (cmH2O), m (SD) 6 (2) 5 (1) 0.20 6 (1) 5 (1) 0.17
PaCO2 (mmHg), m (SD) 88 (14) 81 (14) 0.12 84 (21) 84 (17) 0.90
PaO2:FIO2, m (SD) 139 (39) 169 (50) 0.05 143 (41) 154 (41) 0.55
pH, m (SD) 7.26 (0.07) 7.24 (0.04) 0.14 7.25 (0.06) 7.26 (0.04) 0.44
Respiratory rate (breaths/min), m (SD) 36 (12) 34 (3) 0.64 39 (11) 34 (4) 0.17
Heart rate (bpm), m (SD) 108 (22) 99 (15) 0.14 119 (26) 99 (15) 0.04
Systolic blood pressure (mmHg), m (SD) 149 (31) 129 (12) 0.008 140 (20) 136 (20) 0.60
After 1 h of treatment
PaCO2 (mmHg), m (SD) 72 (12) 62 (10) 0.004 81 (18) 71 (18) 0.22
PaO2:FIO2, m (SD) 193 (43) 222 (61) 0.10 186 (39) 181 (65) 0.82
pH, m (SD) 7.34 (0.06) 7.35 (0.06) 0.74 7.26 (0.05) 7.33 (0.08) 0.02
Respiratory rate (breaths/min), m (SD) 28 (6) 28 (2) 0.87 32 (7) 28 (5) 0.15
Heart rate (bpm), m (SD) 103 (16) 89 (13) 0.002 122 (15) 94 (13) 0.001
Systolic blood pressure (mmHg), m (SD) 135 (24) 124 (17) 0.12 140 (18) 136 (27) 0.61
At end of treatment†
PaCO2 (mmHg), m (SD) 63 (11) 57 (10) 0.08 79 (20) 58 (9) 0.009
PaO2:FIO2, m (SD) 220 (57) 214 (35) 0.66 189 (48) 194 (40) 0.78
pH, m (SD) 7.40 (0.05) 7.40 (0.05) 0.97 7.26 (0.07) 7.39 (0.06) 0.001
Respiratory rate (breaths/min), m (SD) 24 (6) 26 (2) 0.12 33 (10) 27 (5) 0.08
Heart rate (bpm), m (SD) 93 (16) 86 (14) 0.15 121 (21) 86 (7) 0.001
Systolic blood pressure (mmHg), m (SD) 142 (23) 126 (18) 0.02 141 (16) 131 (22) 0.22
Outcome
Duration of NPPV (h), m (SD) 39 (41) 33 (17) 0.07 12 (8) 29 (23) 0.02
Length of stay in ICU (days), m (SD) 14 (14) 10 (16) 0.82 25 (23) 24 (21) 0.90
ICU mortality, No. (%) 1 (4) 1 (5) 0.70 2 (20) 3 (21) 0.66
Hospital mortality, No. (%)‡ 4 (17) 4 (21) 0.53 3 (30) 6 (42) 0.41
* Calculated with the following formula: body weight (kg)/height2 (m). Nine body mass index (BMI) values were missing (four in the helmet group and five in the
mask group). † End of treatment values correspond to when support was discontinued for successful patients and to the time of intubation for those not
responding to noninvasive positive pressure ventilation (NPPV). These values do not include the patient who refused therapy and was discharged alive and
conscious from the hospital (see text). ‡ Hospital deaths include patients who died in the intensive care unit (ICU).
bpm  beats per minute; FIO2  fractional inspired oxygen tension; GCS  Glasgow Coma Score; m  mean; PaCO2  arterial carbon dioxide tension; PaO2 
arterial oxygen tension; PEEP  positive end expiratory pressure; SAPS II  Simplified Acute Physiologic Score II; SD  standard deviation; WBC  white blood
cell.
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axillary vein, probably related to the compression of the
armpit braces that held the helmet in place.
Discussion
This study evaluated the application of NPPV by means
of a helmet to treat patients with acute exacerbation of
COPD who required ICU admission for respiratory fail-
ure. During NPPV the helmet was as effective as a con-
ventional FM in reducing the need for tracheal intuba-
tion, with similar results with regard to ICU and hospital
mortality, length of ICU stay, and rate of infectious com-
plications. Helmet NPPV was better tolerated.
Both techniques achieved improvement in PaO2:FIO2
and a significant decrease in PaCO2. However, the reduc-
tion in PaCO2 was less in the group of patients treated
with the helmet than those treated with the FM. The
helmet and the FM were equally effective in improving
PaO2:FIO2.
A wide consensus exists about the use of NPPV as
first-line treatment for hypercapnic respiratory failure in
patients with acute exacerbation of COPD.4–6 Four ran-
domized, controlled trials, including more than 200 ICU
patients, have evaluated the application of NPPV by FM
in these cases1–3,19. These studies have found that early
application of NPPV significantly improved gas ex-
change, respiratory rate, dyspnea score, and intubation
rates. NPPV also reduced morbidity and mortality in the
ICU and hospital.2
Despite these striking results, approximately 30% of
patients receiving FM NPPV do not respond to treatment
and require intubation.1–5,20 Treatment failure is gener-
ally caused by mask intolerance, uncontrolled leaks, or
lack of improvement in gas exchange.2,13 The helmet is
better tolerated and allows NPPV for prolonged periods,
with minimal air leaks, so it may be a possible alternative
to the FM.
The only existing study on the use of the helmet as an
alternative to the FM for delivering NPPV focused on
patients with acute hypoxemic acute respiratory failure
(not related to COPD).9 We found a similar effect on gas
exchange, intubation rates, ICU, and hospital mortality,
but a significant improvement in patients’ tolerance: no
patients failed to respond to NPPV in the helmet group
because of claustrophobia, discomfort, or pain related to
the technique, compared to 38% of FM patients.9 Pa-
tients in the helmet group tolerated longer periods of
NPPV, despite levels of PEEP higher than those applied
with the FM.9 Those results and those of the present
study suggest a worthwhile advantage of helmet use in
patients with severe hypoxia and hypercapnia, in whom
the continuous, prolonged application of NPPV with
better tolerance and avoidance of skin breakdown can
be crucial.13
In the present study, the treatment failure rate with
noninvasive ventilation was higher than reported else-
where.1–5 This was probably because our patients had
higher severity scores, a large number had pneumonia,
and all met the criteria for mechanical ventilation.
In our study, helmet NPPV reduced hypercapnia less
efficiently than did FM NPPV. Two possible factors
might have influenced this: (1) carbon dioxode rebreath-
ing, and (2) less reduction of inspiratory effort. The
partial pressure of inspired carbon dioxide and end-tidal
carbon dioxide values measured in three healthy volun-
teers (Appendix) showed that carbon dioxide rebreath-
ing with the helmet and the mask is similar and always
less than 1.5%. A less efficient reduction of the inspira-
tory effort may be due to partial dissipation of the in-
spiratory pressure. Part of this pressure is used to ex-
pand the soft collar of the helmet, so the pressurization
rate might be lower than with the FM and sometimes
may affect the trigger and cycling: under this condition,
patient–machine dyssynchrony may occur. In this case,
the patient breathes unassisted into the pressurized hel-
met, similar to breathing in free-flow continuous positive
airway pressure. Currently, the helmet should be
avoided in patients with more severe conditions who
require a rapid increase of alveolar ventilation.
This study adds further evidence that NPPV reduces
the probability of pneumonia.2,20–22 Patients success-
fully treated with NPPV (by helmet or FM) did not
develop pneumonia. All cases of pneumonia in both
groups occurred only after NPPV treatment failure and
intubation. The only helmet-related complication was a
case of deep venous thrombosis in the left axillary vein
in a patient with severe malnutrition, and cachexia,
probably due to prolonged compression from the armpit
brace. Deep venous thrombosis diagnosed after the end
Table 4. Complications
Complications
Helmet
(n  33)
Mask
(n  33) P
Severe, No. (%)
VAP 5 (25) 4 (12) 0.50
Septic shock, severe sepsis 2 (6) 4 (12) 0.33
Acute renal failure 1 (3) 4 (12) 0.17
Sinusitis 0 (0) 2 (6) 0.24
Related to NPPV, No. (%)
Skin breakdown 0 (0) 4 (12) 0.06
Conjunctivitis 0 (0) 2 (6) 0.24
Gastric distension 0 (0) 0 (0) 0.99
Intolerance 0 (0) 6 (18) 0.02
DVT* 1 (3) 0 (0) 0.51
Total 0 (0) 12 (36) 0.001
All ventilator associated pneumonia (VAP) occurred after intubation in patients
who failed to respond to noninvasive positive pressure ventilation (NPPV).
Four cases of community pneumonia (two in each group) progressed to
severe sepsis and septic shock after study entry. In the mask group, the other
two cases of septic shock and severe sepsis were due to urinary tract
infection and central venous catheter–related sepsis.
* Deep venous thrombosis (DVT) occurred in the left axillary vein in one patient
with cancer, who was also cachectic. DVT was due to the prolonged com-
pression of the armpit brace and was documented by echo-color-Doppler.
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of NPPV was successfully managed with anticoagulants.
This suggests that fixation of the braces in severely
malnourished patients needs close attention.
A major criticism to the present study may be directed
toward its design. A case-control study, as opposed to a
randomized trial, is biased toward an overestimation of
the positive effects in the treatment group.23 The limited
value of case-control studies compared to randomized
trials has been partially reappraised in recent systematic
reviews of the literature,24,25 which have concluded that
well-designed observational studies that avoid or consis-
tently reduce the confounding factors are likely to pro-
vide valid results.
The lack of a power analysis is a weakness of the
current study design; however, calculation of a sample
size is based on preexisting data to estimate the baseline
rate of the primary outcome. In fact, to give a priori
hypothesis on expected intubation, the usual intubation
rate of COPD patients treated by helmet should be
known, but no previous data existed on helmet applica-
tion in these patients.
In conclusion, the helmet can be effective in providing
NPPV for COPD patients with acute exacerbation, but it
is less efficient than the FM in carbon dioxide elimina-
tion. Currently, its use should be limited to COPD pa-
tients who do not tolerate the FM in the ICU setting
under strict monitoring.
Appendix
With the helmet, because of the presence of a large volume (6–8 l),
interposed between the inspiratory and expiratory limbs of the venti-
lator circuit, some rebreathing may occur. A substantial amount of the
air delivered by the ventilator at each inflation distends the soft wall of
the helmet and does not actually reach the patient’s airway. To quan-
tify the actual amount of rebreathing occurring while delivering NPPV
with the helmet, compared to the FM, we conducted an experiment in
three healthy volunteers: after a period of 15 min, using a small,
dedicated mouthpiece at the mouth of the subjects, we measured the
end-tidal carbon dioxide and the partial pressure of inspired carbon
dioxide by mainstream capnometry (CO2SMO plus model 8100; Novame-
trix Medical System Inc., Wallingford, CT) with the same helmet and FM
used in the clinical study. In addition, by means of a 3-way connector a 2-l
reservoir bag was placed at the end of the expiratory limb of the respira-
tory circuit, proximally to the expiratory port of a Servo 300 ventilator
(Siemens Elema, Uppsala, Sweden). At the distal end of the reservoir bag,
a stopcock was mounted to collect the exhaled gas in a syringe and
determine the carbon dioxide partial pressure (NovoBiomedical, Statpro-
file Ultra, Waltham, MA). This value represented the actual mean carbon
dioxide partial pressure within the two interfaces, with the ventilator set
in pressure supported ventilation mode with an inspiratory pressure of 10
cmH2O and a positive end expiratory pressure of 5.
The respiratory rates, inspiratory tidal volumes, end-tidal carbon
dioxide, partial pressure of inspired carbon dioxide, and percent car-
bon dioxide were the same in both the helmet and FM groups (table 5).
The carbon dioxide partial pressure values corresponding to the aver-
age carbon dioxide pressure were higher in the FM group, which was
not surprising considering that the air exhaled was diluted in a much
larger volume with the helmet as opposed to the mask. The partial
pressure of inspired carbon dioxide values corresponded to a carbon
dioxide concentration of 0.55% in the FM group and 0.95% in the
helmet group.
These data show that a small amount of rebreathing is present with
both the helmet and the mask but that it is clinically not relevant and
is always below 1.5%.
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